Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Vitamin or precursor
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 938
Molecular formula: C6H5NO2
IUPAC: pyridine-3-carboxylic acid
Source: PC-NIACIN
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Nicotinic acid/vitamin B3; pharmacologic amounts modify lipids, distinct from nicotinamide.
Evidence and critical reading
Reported scientific and empirical uses
Replacement and nutritional context · Cardiovascular and vascular function
Nutritional replacement/defined lipid products; an “HDL improvement” narrative does not replace cardiovascular outcomes.
Human evidence
HPS2-THRIVE evaluated extended-release niacin plus laropiprant in 25,673 patients: no significant vascular-event reduction and more adverse effects. Do not attribute results to every B3 product.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
HPS2-THRIVE evaluated extended-release niacin plus laropiprant in 25,673 patients: no significant vascular-event reduction and more adverse effects. Do not attribute results to every B3 product.
HPS2-THRIVE evaluated extended-release niacin plus laropiprant in 25,673 patients: no significant vascular-event reduction and more adverse effects. Do not attribute results to every B3 product.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Flushing, liver toxicity and glycemic effects matter at pharmacologic amounts; review formulation/lipid-treatment interactions.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Niacin · 1448 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT03356483 · Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.Registry status: CompletedLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07752342 · Exploring Wellbeing Outcomes in Adolescents Using Bifidobacterium Longum, 1714™Registry status: Not yet recruitingLast update posted: October 14, 2026Query verification: October 16, 2026
NCT05398484 · Psilocybin Therapy in Advanced CancerRegistry status: RecruitingLast update posted: October 14, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- ODS-NIACIN
October 16, 2026
- PC-NIACIN
PubChem nicotinic acid (CID 938)
October 16, 2026
- PMID25014686
Effects of extended-release niacin with laropiprant in high-risk patients.
HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J.
October 16, 2026
- SEARCH-PUBMED-niacin
PubMed/MED targeted search: TITLE_ABS:niacin AND TITLE_ABS:HPS2
October 16, 2026